Sandoz Sees Aurobindo Deal Collapse As ‘Opportunity’

Termination Of $1bn Deal Will Allow Firm To ‘Optimize US Business’

 
• By Dave Wallace

Sandoz says closing the door on its proposed deal with Aurobindo will open up opportunities for the Novartis subsidiary to optimize its US business, as global sales for Sandoz shot up by around a tenth in the first quarter of 2020 on the back of a COVID-19 boost and a leap of almost a third in Biopharmaceuticals sales.

Two_Doors
As one door closes, another one opens for Sandoz • Source: Shutterstock

Terminating its proposed deal with Aurobindo to divest its US generic oral solids and dermatology units to the Indian firm for around $1bn will provide Sandoz with an “opportunity to optimize the US business,” the Novartis subsidiary believes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business